- Home
- FULC
as 07-26-2024 4:00pm EST
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Upcoming Earnings Alert:
Get ready for potential market movements as Fulcrum Therapeutics Inc. FULC prepares to release earnings report on 31 Jul 2024.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 382.6M | IPO Year: | 2019 |
| Target Price: | $14.38 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.14 - $13.70 | Next Earning Date: | 07-31-2024 |
| Revenue: | $2,510,000 | Revenue Growth: | -37.95% |
| Revenue Growth (this year): | 1475.4% | Revenue Growth (next year): | -55.96% |
Stock Insider Trading Activity of Fulcrum Therapeutics Inc. (FULC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tourangeau Greg | FULC | Principal Accounting Officer | May 7 '24 | Sell | $7.76 | 236 | $1,831.36 | 11,571 | SEC Form 4 |
| Tourangeau Greg | FULC | Vice President, Finance | Mar 8 '24 | Sell | $11.72 | 4,884 | $57,218.50 | 11,807 | SEC Form 4 |
| Sapir Alex | FULC | See Remarks | Mar 4 '24 | Buy | $11.35 | 43,360 | $492,027.60 | 43,360 | SEC Form 4 |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
Simply Wall St.
14 days ago
Fulcrum Therapeutics (NASDAQ:FULC) delivers shareholders stellar 110% return over 1 year, surging 27% in the last week alone
GlobeNewswire
a month ago
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
Business Wire
a month ago
Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
Compare FULC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.